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Abstract: The need for test systems for nanoparticle biocompatibility, toxicity, and inflam-
matory or adaptive immunological responses is paramount. Nanoparticles should be free of 
microbiological and chemical contaminants, and devoid of toxicity. Nevertheless, in the absence 
of contamination, these particles may still induce undesired immunological effects in vivo, such 
as enhanced autoimmunity, hypersensitivity reactions, and fibrosis. Here we show that artificial 
particles of specific sizes affect immune cell recruitment as tested in a dermal air pouch model in 
mice. In addition, we demonstrate that the composition of nanoparticles may influence immune 
cell recruitment in vivo. Aside from biophysical characterizations in terms of hydrodynamic 
diameter, zeta potential, concentration, and atomic concentration of metals, we show that – after 
first-line in vitro assays – characterization of cellular and molecular effects by dermal air pouch 
analysis is straightforward and should be included in the quality control of nanoparticles. We 
demonstrate this for innate immunological effects such as neutrophil recruitment and the pro-
duction of immune-modulating matrix metalloproteases such as MMP-9; we propose the use 
of air pouch leukocytosis analysis as a future standard assay.
Keywords: nanoparticles, biocompatibility, toxicity, air pouch, immunology
Introduction
Since its inception more than 55 years ago, the air pouch model has been linked with 
cancer research. Hans Selye used the model to study the controversial and contested 
role of inflammation in tumor development and growth. He generated a proximal 
and caudal air pouch on dorsal sites in rats and injected these with Walker tumor 
cell suspensions in combination with irritants or immune suppressants.1 From these 
experiments, he concluded that “a topical inflammatory response can greatly enhance 
the development of transplanted neoplastic tissue,” forecasting that specific inflamma-
tory reactions constitute key driver activities in oncogenic processes.2 Subsequently, 
Selye’s granuloma pouch model was used to study other forms of immunomodula-
tion, for example, by malnutrition and other noxae.3 Another historical example of 
air pouch use was the isolation of a tumor angiogenesis factor (TAF) from Walker 
tumor-elicited ascitic fluid and the demonstration of its angiogenic effect in the rat 
dorsal air sac assay.4
The first use of the air pouch model to study infection and inflammation was also a 
half century ago.5 On the basis of in-depth histopathological studies, it was concluded 
that air pouch formation and the infiltration of leukocytes are dynamic processes in need 
of standardization. The air pouch lining development, including formation of blood 
vessels and a mechanical barrier to retain products, was found to be ideal at 6 days, 
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and cell infiltration was optimal at 24 hours after product 
injection.6 For a considerable time, the rodent air pouch model 
was assumed to reflect the clinical situation of healing wound 
cavities after extirpation of organs.7  Thereafter came a period 
when it was recognized that this model is useful for the study 
of immune reactions, bone and cartilage breakdown, and 
also for drug testing.8–13 In addition to cell infiltrations, the 
production of biological agents, eg, matrix metalloproteinases 
(MMPs), was studied in the pouch exudates.14 Rats were used 
in most of these studies, but these were gradually replaced by 
mice, coincidently with the explosion of genetic and immu-
nological studies using mice for in vivo testing.15 Air pouch 
models were used to study mechanisms of action of drugs, 
pharmacokinetics, enzyme induction or inhibition, regional 
drug delivery, angiogenesis, and cell migration.7,14,16–22 
Gradually, the mouse air pouch model became a standard 
test in pharmacological, immunological, and biomaterials 
research.23–27 With the application of the mouse air pouch 
model, genetic factors, including those encoding cytokines, 
proteinases and other enzymes, and adhesion molecules were 
identified in inflammation; the combination with spontane-
ous gene deficiencies or gene knockout technology further 
enhanced insights into inflammatory processes.28–33
With the introduction of nanomedicines, the awareness 
of immunomodulating effects has increased but still remains 
problematic and challenging. Laboratories are collaborating 
worldwide to define, compare, and validate, not only toxicol-
ogy tests, but also assays to measure effects of nanoparticles 
on immune responses.34 At present, in vivo and ex vivo 
immunological analysis of injected nanoparticles is done by 
studying white blood cells and the histopathology of immune 
organs. Blood analysis yields a partial picture, and histopa-
thology is time consuming and not quantitative. For immuno-
logical screening of nanomedicines, these tests are important 
but not sufficient – for at least three reasons. First, all viruses, 
except the largest (pox and pandora) viruses, are (replicating) 
nanostructures that exert profound immunological effects in 
vivo, even after being completely inactivated, for instance, 
in vaccines. Nanoparticles, in particular those that are (un)
purposely coated with proteins or those having nucleic acids, 
are therefore virus mimetics. It is generally accepted that 
pattern recognition receptors, such as Toll-like or retinoic 
acid-inducible gene (RIG)-like receptors, induce the imme-
diate innate immune response to nanoparticulate viruses. 
Nanoparticles also help with ensuing adaptive responses 
to generate antigen-specific T cell responses and antibody 
formation by B lymphocytes. In addition, specific cell types 
in organisms can sense the size of particles (infectious agents 
range in size from nanometers for viruses, micrometers for 
bacteria and parasites, to  millimeters, centimeters, or even 
meters for worms). Second, host immunity is by definition 
based on organ systems that cannot be replaced by single 
cells. For instance, antigenicity is tested by the ability to 
form antibodies in vivo; such a test is difficult to reproduce 
in vitro. Third, the available in vivo toxicity tests for nanopar-
ticles include skin painting, inhalation (airway provocation), 
and ingestion. These tests are excellent means by which to 
establish safety measures against potential dangers of profes-
sional exposure of workers in research and manufacturing. 
However, in all the aforementioned cases, epithelial barri-
ers of skin and mucosa are involved. Most nanomedicines 
will, in practice, be used by injection and therefore will first 
encounter leukocytes, and endothelial and mesothelial cells, 
rather than epithelial cells. For these reasons, a profound need 
exists for one or more standard tests that can measure various 
aspects of immunological responses. In view of increasing 
biomedical applications of nanoparticles as drugs or imaging 
tools, immunotoxicity analysis needs standardization.35,36 In 
this study, we present data on the use of air pouch analysis 
of nanoparticles toward this goal.
Materials and methods
The mouse air pouch model
A general outline of the method used is shown in  Figure 1A. 
Dermal air pouches were established by injecting Naval 
Medical Research Institute mice on dorsal sites with 3 mL 
filtered air (0.20 µm filter) on days 0 and 3.37 On day 6, the test 
samples were injected, along with a negative and a positive 
control sample.  Phosphate-buffered saline (PBS) was used as 
a negative control and chlorite-oxidized oxyamylose (COAM) 
as a positive control, for neutrophil recruitment.38 After 
24 hour contact, the exudates of the pouches were collected 
after injection of 1 mL pyrogen-free PBS containing heparin 
20 U/mL and 2% fetal calf serum (FCS), and followed by 
30 seconds of gentle massage. This procedure was repeated 
twice with 2 mL buffer, and the total exudate collection was 
centrifuged (10 minutes, 900 rpm). The numbers of viable 
cells were determined in a Bürker chamber after trypan blue 
exclusion of dead cells and were resuspended for immedi-
ate hemocytometry and cytospin analysis. The supernatant 
fluids were frozen (-20°C) for gelatin zymography.39 Each 
sample was tested for contamination with endotoxin using 
the Limulus amebocyte lysate test (Cambrex Bio Science, 
Baltimore, MD, USA). All procedures were conducted in 
accordance with protocols approved by the local Ethics 
 Committee (Licence number P028/2013, Belgium). All 
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Figure 1 Optimization of the air pouch model. 
Notes: (A) schematic outline of the air pouch model. at the start of the test, 3 ml air is injected through a sterile 0.20 µm filter at a dermal site of a mouse to form a 
pouch. On the third day, this action is repeated. Products are injected on day 6 after the start and their cellular and molecular effects are measured 24 hours later by retrieval 
of cells and molecules within the pouch exudates. (B–D) cOaM induces a dose-dependent recruitment of neutrophils and can be used as a standard for the air pouch 
model. The air pouch model was executed in the standard setting of 6 day formation and 24 hour contact time for test samples. cOaM was used at different doses. Three 
possible read-outs are shown: (B) increase (and saturation) of percentage neutrophils, (C) decrease of macrophage percentages and (D) decrease of percentage lymphocytes 
(n=5 for all test samples). The positive control reached saturation at 1 mg cOaM per pouch. (E) analysis of the absolute numbers of retrieved cells per pouch. (F and G) 
correlation between Facs and cytospin data from mouse air pouches. (F) correlation (two-tailed parametric correlation analysis) between percentages of neutrophils 
(polymorphonuclear cells) as measured by Facs analysis and cytospin analysis (r=0.80, n=45). Linear regression was performed and found to be significant (P,0.0001). 
(G) correlation (two-tailed parametric correlation analysis) of percentages mononuclear cells as measured by Facs analysis and cytospin analysis (r=0.58, n=79). linear 
regression was performed and found to be significant (P,0.0001). 
Abbreviations: COAM, chlorite-oxidized oxyamylose; FACS, fluorescence-activated cell sorting; PBS, phosphate-buffered saline.
materials were tested on three to five mice. In addition, the 
statistical analysis and the repeat numbers of the positive 
(COAM) and negative (PBS) controls have been indicated in 
Table 1. Finally, most nanoparticles were tested twice (with 
similar results), depending on material availability.
Differential cell counts
Differential cell counts were based on morphologic 
 examination of cytospin preparations stained with Hema-
color (Merck Chemicals, Darmstadt, Germany). 75 × 103 
cells were applied onto slides by centrifugation using 
a  Shandon Cytospin 2 apparatus (Thermo Shandon, 
 Pittsburgh, PA, USA).
Flow cytometry analysis
To corroborate hemocytometric analyses, we also performed 
flow cytometry analysis. The rationale for this was two-fold. 
First, many laboratories are equipped with cytometers to dif-
ferentiate by immunophenotyping cell numbers in an efficient 
way. Second, it was used to validate the more labor-intensive 
microscopic quantification. We incubated 5 × 105 cells for 
15 minutes with the Fc-receptor-blocking antibodies anti-
International Journal of Nanomedicine 2013:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4748
Vandooren et al
Table 1 The effect of different sets of nanoparticles according to the air pouch test
Production Nanoparticle††† LAL assay (pg/mg) Cells (×106) per air pouch % Neutrophils
PBs #12.5* 0.77±0.39† 37.8±6.9††
cOaM 13.3 1.53±0.51† 60.7±7.7††
BIU, Israel caNsmaghemite NPs1a 28.4 2.77 76
BIU, Israel Type I PeI-caN-maghemite1b #9.3 0.91 88
BIU, Israel Type II PeI-caN-maghemite1c 42.5 2.83 55
cIDeTec, spain PDMaeMa-scPNs2a 562.5 1.75 89
cIDeTec, spain PMaac-scPNs2b 762.5 0.45 56
UNIBO, Italy Plga-cOOh3a #3.1 0.9 34
UNIBO, Italy Plga-b-Peg-cOOh3b 12.5 1.1 39
UNIBO, Italy Magh@PNPs3c 41.7 1.22 44
gU, germany lNP lII4a 12 0.89 59
gU, germany caN cIII4b #1.3 0.74 39
Notes: †The amount of cells per air pouch in the PBs and cOaM conditions was calculated over a set of seven experiments with three mice per condition. The values 
are shown as mean ± SD. The PBS and COAM groups were significantly different as calculated with a paired t-test (n=7, P=0.0043). ††The percentage of neutrophils per air 
pouch in the PBs and cOaM conditions were calculated over a set of seven experiments with three mice per condition. The values are shown as mean ± sD. The PBs and 
COAM groups were significantly different as calculated with a paired t-test (n=7, P=0.0032). †††Identification and characteristics of nanoparticles: 1a–c: (1a) CAN-γ-Fe2O3 NPs: 
average NP diameter 7.61 ± 2.33 nm (TeM), weight ratio ce/Fe: 0.029; (1b) Type I PeI25-caN-γ-Fe2O3 NPs: average NP diameter 6.50 ± 2.15 nm (TeM), 71.2–96.56 nm (Dls 
average hydrodynamic NP diameter), ζ potential: +23.0–24.0 mV; weight ratio ce/Fe: 0.095; (1c) Type II PeI8-caN-γ-Fe2O3 NPs: average NP diameter 7.65 ± 2.64 nm (TeM), 
58.0–62.0 nm (Dls average hydrodynamic NP diameter), ζ potential: +56.3 mV; weight ratio ce/Fe: 0.100. 2a and b: (2a) PDMaeMa-scPNs: N,N′-dimethylaminoethyl 
methacrylate-based single chain polymer nanoparticles, ±13 nm (Dls), ζ potential: +11.5, (2b) PMaac based scPNs: polymethacrylic acid-based single chain polymer 
nanoparticles, ±17 nm (Dls); 3a–c: (3a) Plga-cOOh: average NP diameter 160 nm, ζ potential: -55.1 mV, PDI: 0.078, (3b) Plga-b-Peg-cOOh: average NP diameter 
74 nm, ζ potential: -11.5 mV, PDI: 0.095; (3c) Magh@PNPs: average NP diameter 92.3 nm, ζ potential: -7.56 mV, PDI: 0.098. 4a and b: (4a) lNP lII: average NP diameter 
193 ± 1 nm, ζ potential: -41.9 ± 0.7 mV, PDI: 0.023 ± 0.021, (4b) caN cIII: average NP diameter 191 ± 1 nm, ζ potential: -52.7 ± 0.3 mV, PDI: 0.027 ± 0.035. *For PBs the 
endotoxin analysis was obtained per ml volume. For all other products we calculated the endotoxin level/mg pure product.
Abbreviations: BIU, Bar-Ilan University; caN, ceric ammonium nitrate; cIDeTec, Fundación cIDeTec; cOaM, chlorite-oxidized oxyamylose; Dls, dynamic light 
scattering; gU, goethe-Universität; lal, limulus amebocyte lysate; lNP, lipid nanoparticle; Magh, Maghemite; n, number; NP, nanoparticle; PBs, phosphate-buffered saline; 
PDI, polydispersity index; PDMaeMa, poly(N,N-dimethylaminoethyl methacrylate); Peg, polyethylene glycol; PeI, polyethyleneimine; Plga, poly(D,l-lactide-co-glycolide); 
PMaac, polymethacrylic acid; PNP, polymeric nanoparticles; scPN, single-chain polymeric nanoparticle; TeM, transmission electron microscopy; UNIBO, University of 
Bologna; sD, standard deviation.
CD16/anti-CD32 (BD Biosciences Pharmingen, San Diego, 
CA, USA), washed with PBS + 2% FCS and then stained 
for 30 minutes with the indicated fluorescein isothiocyanate 
(FITC)-conjugated, phycoerythrin (PE)-conjugated and 
allophycocyanin (APC)-conjugated antibodies. Cells were 
washed twice and fixed with 0.37% formaldehyde in PBS. 
FITC-conjugated anti-CD11b, PE-conjugated anti-CD4, 
FITC-CD8, PE-conjugated Gr-1 (granulocyte-differentiation 
antigen-1), and APC-conjugated F4/80 were purchased from 
eBioscience, Inc (San Diego, CA, USA). Cells were analyzed 
on a fluorescence-activated cell sorting (FACS) Calibur 
flow cytometer (Becton Dickinson, San Jose, CA, USA) 
and data were processed with the manufacturer’s CellQuest 
software.38
gelatin zymography
Gelatin zymography was used to measure the presence of the 
MMP-2 and the inducible MMP-9.39,40 All samples were first 
prepurified by gelatin-Sepharose affinity chromatography, 
as described in a previous publication.41 Next, the proteins 
were separated in 7.5% polyacrylamide gels to which 0.1% 
gelatin (Sigma-Aldrich, St Louis, MO, USA) was added and 
copolymerized. After electrophoresis, the gels were washed 
to remove sodium dodecyl sulfate and incubated for the 
development of zymolytic bands. The gels were stained with 
Coomassie brilliant blue R-250 (Sigma-Aldrich).
Results
Validation of the mouse air pouch model
First, the use of COAM as a positive control substance was 
evaluated (Figure 1B–E). Injection of COAM resulted in a 
dose-dependent increase in the number of total viable cells. 
Differential cell counts revealed that mostly neutrophils 
migrated into air pouches. Therefore, in all forthcoming 
experiments 2 mg of COAM was used as a positive control 
for neutrophil recruitment. Upon collection of the samples, we 
first counted and differentiated the cells by classical hemocy-
tometric analysis. With this approach a trained microscopist 
can differentiate neutrophils from monocytes/macrophages 
and lymphocytes, and this technique does not necessitate the 
purchase of expensive equipment. To validate this approach 
and to demonstrate that, alternatively, flow cytometric analy-
sis with the use of cell-specific antibodies is another way of 
quantification, correlation analysis was done for neutrophil 
and mononuclear cell counts for both techniques (Figure 1F 
and G). Our data indicate that both methods are suitable for 
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quantification and differential cell counting of specific leu-
kocyte subsets, and that more sophisticated and high-end cell 
differentiations with flow cytometric analysis are possible.
analysis of differently sized  
polystyrene particles
In a first set of experiments we evaluated the effect of poly-
styrene particles of different sizes on the recruitment of leu-
kocytes and the content of gelatinases (MMP-2 and MMP-9). 
Because MMP-9 is highly expressed by leukocytes upon 
an inflammatory stimulus, we hypothesized that immune-
modulating substances would increase the ratio of MMP-9/
MMP-2.40,42 Indeed, in gelatin zymography analysis,39 
MMP-2 is found constitutively expressed in most tissues 
and body fluids. Consequently, MMP-2 may be used as an 
internal reference enzyme. In contrast, MMP-9 is an induc-
ible enzyme in cancer, infection, and inflammation, which 
makes the MMP-9/MMP-2 ratios indicative for neoplastic, 
infectious, or inflammatory processes.
Whereas COAM and polystyrene nanoparticles induced 
more than a doubling in the numbers of total retrieved cells 
in comparison with PBS control samples, the microspheres 
did not (Figure 2A). When we differentially counted leuko-
cytes in this pilot experiment, we observed twice as many 
neutrophils after nanoparticle and microparticle injection 
than with the PBS control, which recruited more mononu-
clear cells (Figure 2B and C). Zymography analysis of the 
exudate fluids demonstrated a clear induction of gelatinase 
B/MMP-9 by COAM and by the polystyrene nanospheres, 
but less with microspheres. As expected, the cellular 
infiltration was correlated with the induction of MMP-9; 
these findings illustrated the inflammatory context of air 
pouches at the molecular level after injection of COAM 
(Figure 2D and E).
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Figure 2 analysis of polystyrene particles with different sizes in air pouches. 
Notes: Particles were either endotoxin-free polystyrene nanoparticles (100 nm) or polystyrene microspheres with a diameter of 1 µm. (A) analysis of the absolute 
numbers of retrieved cells. (B) The relative numbers of leukocytes as determined by hemocytometry and as corroborated by Facs analysis. (C) Illustration of cytospin 
preparations stained with hemacolor and higher magnifications of the cells in the insets. (D) Illustration of gelatin zymography analysis of air pouch fluids. Gelatinase A/
matrix metalloproteinase-2 (MMP-2) is constitutively expressed in all samples and gelatinase B/MMP-9 is up regulated after injection of cOaM or polystyrene nanoparticles. 
(E) scanning densitometry analysis of gelatin zymograms. The MMP-9 content is expressed as the ratios of MMP-9 versus constitutive MMP-2. The results illustrate the acute 
inflammatory context of air pouches, after COAM treatment, at the molecular level. Clearly, cellular infiltration is correlated with the induction of MMP-9. 
Abbreviations: COAM, chlorite-oxidized oxyamylose; FACS, fluorescence-activated cell sorting; MMP, matrix metalloproteinase; PBS, phosphate-buffered saline.
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analysis of core nanoparticles
Sets of different nanoparticles with different chemical char-
acteristics and manufacturing procedures were compared in 
the dermal air pouch system with negative (PBS) and posi-
tive (COAM) control samples (Table 1 and Supplementary 
materials). First, all samples were tested for contamination 
with endotoxin. Most particles did not exceed the endotoxin 
limit of 100 pg/mL (US Food and Drug Administration 
standard for substances in direct/indirect contact with the 
cardiovascular system or lymphatic system). However, sev-
eral nanoparticles attracted higher percentages of neutrophils, 
resulting in higher total cell counts in comparison with the 
negative control.
Discussion
Most reviews on safety, toxicity and immunological effects of 
nanoparticles use in vitro analyses. Without any doubt, such 
tests are paramount and essential first-line analytical tools 
for the measurement of cytotoxicity and eventual metabolic 
effects.34–36 However, the effects of nanoparticles on in vitro 
cultured macrophages, dendritic cells, neutrophils, and 
lymphocytes, in terms of release of inflammatory (eg, pros-
taglandins) or immunological mediators (eg, enzymes and 
cytokines) are insufficient to determine immunotoxicity.
The next step, second-line analytical tools for in vivo test-
ing, logically starts with the analysis of blood components. 
Hematological parameters should include effects on the clot-
ting and fibrinolytic systems, and blood cell counts for eryth-
rocytes (hemolysis), platelets and leukocytes. Immunological 
parameters, such as complement pathway tests, immuno-
globulin levels, and FACS analysis of leukocyte subsets, may 
be added to immunological tests for  nanoparticles. Another 
second-line immunological test may consist of histopathol-
ogy analysis of immune organs, including bone marrow, 
thymus, lymph nodes and spleen. Practically, however, this 
constitutes a time-consuming and high-end analysis needing 
the expertise of well-trained pathologists.34–36 Therefore, a 
second-line in vivo test,  amenable to standardization and 
routine analysis is proposed. The air pouch model fulfills the 
criteria as such a test for several reasons: 1) it constitutes a 
surrogate test for histopathology analysis of immune reac-
tions including tissue inflammation;6 2) dependent on the 
execution and standardization, it yields (semi-) quantitative 
results in the form of absolute and relative leukocyte counts; 
3) it can be used to study acute and chronic immune reac-
tions; 4) it can be executed with limited costs and in simple 
laboratory environments by well-trained technicians, and 
with basic infrastructure; and 5) it can even be used to test the 
effects of (immunomodulating) gases, such as NO or H
2
S, or 
of nanoparticles that might generate gases by catalysis.
An important issue to address is the minimization of use 
of mammalian hosts for in vivo testing. Unfortunately, immu-
nological testing requires in vivo experiments, but in practice 
the air pouch test yields solid and reproducible data with 
minimally three mice per test sample. Although we propose 
to use the air pouch leukocytosis analysis as a standard tech-
nique for in vivo testing of nanoparticles and suggest using 
buffer conditions as negative and COAM as positive controls, 
we acknowledge that additional studies will demonstrate its 
value. Figure 1B–E illustrates the variability within groups 
of five mice, whereas the statistical analysis of the PBS and 
COAM controls in Table 1 (seven groups, three mice per 
group) illustrates the reproducibility. Many mouse strains are 
genetically and immunologically well characterized and can 
be housed in a cost-effective way in comparison with larger 
mammals. Also, it needs to be stated that with the mouse 
air pouch model, the distress and suffering of the animals is 
limited in comparison with efficacy testing of nanoparticles, 
for instance, in mouse tumor models. As alternative to the air 
pouch test, we also used intraperitoneal injection.43 Because 
the peritoneal cavity is a larger space, dilution of samples 
occurs and, in addition, sample retrieval is more variable and 
demands better skills. The air pouch test can be executed by 
any well-trained scientist and, in principle, does not need 
sophisticated  equipment. In addition, analysis methods on 
retrieved cells and exudate molecules can be upgraded to 
high-end cyto metry and molecular analysis, including RNA 
sequencing, proteomics, and glycomics analysis. This is here 
illustrated with one analysis of gelatinases by zymography.39 
As is the case of in vitro tests, any in vivo test will have limita-
tions. Coating with host molecules (eg, nanoparticle corona) 
may lead to immunological side effects in vivo.34 In contrast 
to organic biodegradable nanoparticles, including small virus 
particles, many nanoparticles with inorganic cores are not 
degradable, may persist and yield chronic deposition in tis-
sues, sterile granuloma formation, and fibrosis. These aspects, 
and comparisons between degradable and nondegradable 
particles, may also be studied in the future by observations 
of air pouches after prolonged time intervals.
Conclusion
We conclude that standardized air pouch leukocytosis 
analysis fulfills the criteria as a test for innate immune 
functions and is also amenable for analysis of changes 
in adaptive immune functions, and we advocate the use 
of this  analytical method. With microbial, pyrogenicity, 
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cytotoxicity and in vitro immunological tests (eg, cytokine 
induction on specific cells) as first-line assays, the dermal 
air pouch analysis is – in addition to hematology param-
eters – a valuable tool to be implemented as second-line 
assay for all present and future nanomedicines. Experi-
mental animal models for human disease are necessary for 
medical progress toward better diagnosis, prognoses, and 
therapies. Awareness of ethical issues has progressively 
diminished the use of mammalian vertebrates and led to a 
switch towards the use of frogs, zebrafish, worms, snails, 
and flies. Although ortholog models for many diseases 
already exist in these species, in particular for neurobiologi-
cal research, for immunological evaluations and research 
such species replacement strategy is not broadly applicable. 
Because inflammation and adaptive immune mechanisms 
are increasingly being found to be important in tumor biol-
ogy and nanoparticles are hailed as carriers for new cancer 
drugs, nanoparticle research for oncology applications 
needs to rely on evaluations by mammalian host experi-
ments – such as the air pouch test. We recommend using 
only those nanoparticles parenterally (eg, for diagnostic 
purposes) that yield air pouch leukocytosis, equivalent to 
the negative PBS control.
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Figure S1 caN-γ-Fe2O3, type I PeI25-caN-γ-Fe2O3 and type II PeI25-caN-γ-Fe2O3 NPs TeM and size distribution. 
Notes: (A) caN-γ-Fe2O3 NPs (left) TeM microphotograph; (right) size distribution histogram of 7.61±2.33 nm-sized caN-γ-Fe2O3 NPs. (B) Type I PeI25-caN-γ-Fe2O3 NPs 
(left) TeM microphotographs; (right) size distribution histogram of averaged 6.50±2.15 nm-sized Type I PeI25-caN-γ-Fe2O3 NPs. (C) Type II PeI8-caN-γ-Fe2O3 NPs (left) 
TeM microphotographs; (right) size distribution histogram of averaged 7.65±2.64 nm-sized Type II PeI25-caN-γ-Fe2O3 NPs. 
Abbreviations: NP, nanoparticle; PeI, polyethylene imine; TeM, transmission electron microscopy.
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Figure S2 PDMaeMa and PMaac scPNs dynamic light scattering (Dls) and atomic force microscopy (aFM) images. 
Notes: (A) PDMaeMa scPNs (left) Dls measurement data: average size of 13±2.9 nm, and (right) aFM picture of dry nanoparticles around 3 nm in size; (B) PMaac scPNs 
(left) Dls measurement data: average size of 16±4.2 nm; and (right) aFM picture of dry nanoparticles around 5 nm in size.
Abbreviations: PDMaeMa, poly(N,N-dimethylaminoethyl methacrylate); PMaac, polymethacrylic acid; scPN, single-chain polymeric nanoparticle.
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Figure S3 Plga-cOOh NPs, Plga-b-Peg-cOOh NPs and Magh@PNPs size distribution histograms, zeta potentials and transmission electron microscopy images. 
Notes: (A) Plga-cOOh NPs (top) size distribution histogram; (bottom) ζ potential of Plga-cOOh NPs; (B) Plga-b-Peg-cOOh NPs (top) size distribution histogram; 
(bottom) ζ potential of Plga-b-Peg-cOOh NPs; (C) Magh@PNPs (top) size distribution histogram, (middle) ζ potential, and (bottom) TeM microphotographs of Magh@PNPs. 
Abbreviations: NP, nanoparticle; Peg, polyethylene glycol; Plga, poly(D,l-lactide-co-glycolide); PNPs, polymeric nanoparticles; TeM, transmission electron microscopy. 
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